Synergy Between Chemotherapeutic Agents and CTLA-4 Blockade in Preclinical Tumor Models

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2013 Jul 23

PMID 23873089

Citations 36

Authors

Maria Jure-Kunkel

Gregg Masters

Emel Girit

Gennaro Dito

Francis Lee

John T Hunt

Rachel Humphrey

Affiliations

Soon will be listed here.

Abstract

Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) binding agent, has proven to be an effective monotherapy for metastatic melanoma and has shown antitumor activity in trials when administered with other therapeutic agents. We hypothesized that the combination of ipilimumab with chemotherapeutic agents, such as ixabepilone, paclitaxel, etoposide, and gemcitabine, may produce therapeutic synergy based on distinct but complementary mechanisms of action for each drug and unique cellular targets. This concept was investigated using a mouse homolog of ipilimumab in preclinical murine tumor models, including SA1N fibrosarcoma, EMT-6 mammary carcinoma, M109 lung carcinoma, and CT-26 colon carcinoma. Results of CTLA-4 blockade in combination with one of various chemotherapeutic agents demonstrate that synergy occurs in settings where either agent alone was not effective in inducing tumor regression. Furthermore, when combined with CTLA-4 blockade, ixabepilone, etoposide, and gemcitabine elicited prolonged antitumor effects in some murine models with induction of a memory immune response. Future investigations are warranted to determine which specific chemo-immunotherapy combinations, if any, will produce synergistic antitumor effects in the clinical setting.

Citing Articles

The cardio-oncologic burden of breast cancer: molecular mechanisms and importance of preclinical models.

Brauer J, Tumani M, Frey N, Lehmann L Basic Res Cardiol. 2024; 120(1):91-112.

PMID: 39621070 PMC: 11790711. DOI: 10.1007/s00395-024-01090-w.

A novel doxorubicin/CTLA-4 blocker co-loaded drug delivery system improves efficacy and safety in antitumor therapy.

Yang W, Sun Q, Zhang X, Zheng L, Yang X, He N Cell Death Dis. 2024; 15(6):386.

PMID: 38824143 PMC: 11144200. DOI: 10.1038/s41419-024-06776-6.

The Application of Biomedicine in Chemodynamic Therapy: From Material Design to Improved Strategies.

Cheng B, Li D, Li C, Zhuang Z, Wang P, Liu G Bioengineering (Basel). 2023; 10(8).

PMID: 37627810 PMC: 10451538. DOI: 10.3390/bioengineering10080925.

Global research trends on immunotherapy in cancer: A bibliometric analysis.

Yao Z, Lin Z, Wu W Hum Vaccin Immunother. 2023; 19(2):2219191.

PMID: 37314453 PMC: 10269390. DOI: 10.1080/21645515.2023.2219191.

Revising the Landscape of Cytokine-Induced Killer Cell Therapy in Lung Cancer: Focus on Immune Checkpoint Inhibitors.

Vaseq R, Sharma A, Li Y, Schmidt-Wolf I Int J Mol Sci. 2023; 24(6).

PMID: 36982701 PMC: 10054817. DOI: 10.3390/ijms24065626.

References

Lynch T, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R . Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012; 30(17):2046-54. DOI: 10.1200/JCO.2011.38.4032. View

Ribas A, Camacho L, Lopez-Berestein G, Pavlov D, Bulanhagui C, Millham R . Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005; 23(35):8968-77. DOI: 10.1200/JCO.2005.01.109. View

Rudd C, Taylor A, Schneider H . CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev. 2009; 229(1):12-26. PMC: 4186963. DOI: 10.1111/j.1600-065X.2009.00770.x. View

Nowak A, Robinson B, Lake R . Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res. 2003; 63(15):4490-6. View

Walunas T, Lenschow D, Bakker C, Linsley P, Freeman G, Green J . CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994; 1(5):405-13. DOI: 10.1016/1074-7613(94)90071-x. View

Fong L, Small E . Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol. 2008; 26(32):5275-83. DOI: 10.1200/JCO.2008.17.8954. View

Phan G, Yang J, Sherry R, Hwu P, Topalian S, Schwartzentruber D . Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003; 100(14):8372-7. PMC: 166236. DOI: 10.1073/pnas.1533209100. View

Sharpe A . Mechanisms of costimulation. Immunol Rev. 2009; 229(1):5-11. PMC: 2928676. DOI: 10.1111/j.1600-065X.2009.00784.x. View

Whiteside T . Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther. 2010; 10(7):1019-35. PMC: 2882984. DOI: 10.1517/14712598.2010.482207. View

10.

Krummel M, Sullivan T, Allison J . Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. Int Immunol. 1996; 8(4):519-23. DOI: 10.1093/intimm/8.4.519. View

11.

Ramakrishnan R, Assudani D, Nagaraj S, Hunter T, Cho H, Antonia S . Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest. 2010; 120(4):1111-24. PMC: 2846048. DOI: 10.1172/JCI40269. View

12.

Krummel M, Allison J . CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med. 1996; 183(6):2533-40. PMC: 2192613. DOI: 10.1084/jem.183.6.2533. View

13.

Korman A, Peggs K, Allison J . Checkpoint blockade in cancer immunotherapy. Adv Immunol. 2006; 90:297-339. PMC: 1951510. DOI: 10.1016/S0065-2776(06)90008-X. View

14.

Qureshi O, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt E . Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011; 332(6029):600-3. PMC: 3198051. DOI: 10.1126/science.1202947. View

15.

Shurin G, Tourkova I, Kaneno R, Shurin M . Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol. 2009; 183(1):137-44. PMC: 4005417. DOI: 10.4049/jimmunol.0900734. View

16.

Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G . Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2007; 8(1):59-73. DOI: 10.1038/nri2216. View

17.

Linsley P, Greene J, Brady W, Bajorath J, Ledbetter J, Peach R . Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity. 1994; 1(9):793-801. DOI: 10.1016/s1074-7613(94)80021-9. View

18.

Tivol E, Borriello F, Schweitzer A, Lynch W, Bluestone J, Sharpe A . Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995; 3(5):541-7. DOI: 10.1016/1074-7613(95)90125-6. View

19.

Zigler M, Villares G, Lev D, Melnikova V, Bar-Eli M . Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape. Am J Clin Dermatol. 2008; 9(5):307-11. DOI: 10.2165/00128071-200809050-00004. View

20.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View